Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Chlamydia trachomatis | DNA ligase | 0.0012 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Plasmodium vivax | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | Activator 1 140 kDa subunit, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | NAD-dependent DNA ligase, Lig | 0.0012 | 0 | 0.5 |
Giardia lamblia | Replication factor C, subunit 1 | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Treponema pallidum | DNA ligase (lig) | 0.0012 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Toxoplasma gondii | ATPase, AAA family protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | replication factor C large subunit, putative | 0.0012 | 0 | 0.5 |
Plasmodium falciparum | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE DNA LIGASE [NAD DEPENDENT] LIGA (POLYDEOXYRIBONUCLEOTIDE SYNTHASE [NAD+]) | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Mycobacterium ulcerans | NAD-dependent DNA ligase LigA | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | FHA domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 37.933 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.